Abstract

BackgroundIt has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis.ObjectivesThe objective of this study was to investigate the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0773 Effectiveness of golimumab in tnf-inhibitor inadequate responder patients with spondyloarthritis and psoriatic arthritis
Pcf Falappone ... F Iannone
Annals of the Rheumatic Diseases | VOL. 76
Pcf Falappone, et. al.Pcf Falappone ... F Iannone
01 Jun 2017
SAT0087 REAL-LIFE GOLIMUMAB PERSISTENCE IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: FINAL RESULTS OF THE GO-PRACTICE STUDY
...
-
, et. al. ...
01 Jun 2019
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
Anastas Batalov ... Salvatore D'Angelo
Clinical and experimental rheumatology | VOL. 42
Anastas Batalov, et. al.Anastas Batalov ... Salvatore D'Angelo
26 Apr 2023
FRI0094 LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG
Bjørg Tilde Svanes Fevang ... Andreas Diamantopoulos
-
Bjørg Tilde Svanes Fevang, et. al.Bjørg Tilde Svanes Fevang ... Andreas Diamantopoulos
01 Jun 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers